Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Home
Next Post
Previous Post
test
September 30, 2023
/
Uncategorized
1
Like
Share
the Post
About
the Author
webmaster
Related
Posts
Management of adverse events in the AMPECT trial of
nab
-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Correlation of
nab
-sirolimus tumor drug levels and improved tumor suppression in
KRAS G12C
non-small cell lung cancer xenografts treated with
nab
-sirolimus in combination with KRAS inhibitors
A phase I/II multicenter study of ABI-009 (
nab
-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of
nab
-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.